BioSpace News Archive

Verismo Therapeutics today announced that an abstract has been accepted for oral presentation at the upcoming American Society of Gene & Cell Therapy 2024 (ASGCT 2024), to be held in Baltimore on May 7-11, 2024.

GE HealthCare, a leader in precision care innovation, will host an investor day on Thursday, November 21, 2024, in New York, NY.

Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN® (nadofaragene firadenovec-vncg) were presented at the American Urological Association (AUA) 2024 Annual Meeting.

Ansa Biotechnologies, Inc. today announced that it is expanding its early access program for its complex DNA synthesis services.

bluebird bio, Inc. announced that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET.

Xeris Biopharma Holdings, Inc. announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.

Stoke Therapeutics, Inc. reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.

bluebird bio, Inc. announced that it has completed the first commercial cell collection for LYFGENIA, a one-time gene therapy for the treatment of sickle cell disease in patients with a history of vaso-occlusive events.

Annovis Bio, Inc. announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps.

Soligenix, Inc. announced that the Company will deliver a corporate presentation at the upcoming conferences below.